Abstract
Cancer immunotherapy, a new weapon against cancers by harnessing the patient's own immune system, potentiates an extended remission and possibly a cure for cancer. T cells genetically engineered with chimeric antigen receptor (CAR) vectors can specifically target the surface antigen of cancer cells and kill them in an MHC-independent manner. CD19 is extensively expressed on cancerous cells in B cell malignancies. To target this antigen, CAR T cells have gained great success in treating patients with B cell leukemia and lymphoma. Currently, the data from clinical trials on CAR T cells in solid tumors are limited; thus, CAR T cells targeting GD2, HER2, EGFRvIII, CSPG4, DNAX, mesothelin, and other molecules are under active investigation for solid tumors. In this review, we summarize the clinical results for CAR T cells in the case of hematologic and solid tumors, along with the current developments in CAR T cell immunotherapy.
Keywords: Cancer immunotherapy, CAR T cells, hematologic malignancies, solid tumor, cancer cells, leukemia.
Current Stem Cell Research & Therapy
Title:Chimeric Antigen Receptor T Cell Based Immunotherapy for Cancer
Volume: 13 Issue: 5
Author(s): Feng Li, Tengfei Zhang, Ling Cao and Yi Zhang*
Affiliation:
- Biotherapy Center, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan,China
Keywords: Cancer immunotherapy, CAR T cells, hematologic malignancies, solid tumor, cancer cells, leukemia.
Abstract: Cancer immunotherapy, a new weapon against cancers by harnessing the patient's own immune system, potentiates an extended remission and possibly a cure for cancer. T cells genetically engineered with chimeric antigen receptor (CAR) vectors can specifically target the surface antigen of cancer cells and kill them in an MHC-independent manner. CD19 is extensively expressed on cancerous cells in B cell malignancies. To target this antigen, CAR T cells have gained great success in treating patients with B cell leukemia and lymphoma. Currently, the data from clinical trials on CAR T cells in solid tumors are limited; thus, CAR T cells targeting GD2, HER2, EGFRvIII, CSPG4, DNAX, mesothelin, and other molecules are under active investigation for solid tumors. In this review, we summarize the clinical results for CAR T cells in the case of hematologic and solid tumors, along with the current developments in CAR T cell immunotherapy.
Export Options
About this article
Cite this article as:
Li Feng , Zhang Tengfei , Cao Ling and Zhang Yi *, Chimeric Antigen Receptor T Cell Based Immunotherapy for Cancer, Current Stem Cell Research & Therapy 2018; 13 (5) . https://dx.doi.org/10.2174/1574888X13666180420110239
DOI https://dx.doi.org/10.2174/1574888X13666180420110239 |
Print ISSN 1574-888X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3946 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cellular Therapy of Lysosomal Storage Disorders: Current Status and Future Prospects
Current Pediatric Reviews Functional Evaluation of an Ectopic Supernumerary Kidney in Pelvis
Current Medical Imaging New Generation of Liposomes Called Archaeosomes Based on Natural or Synthetic Archaeal Lipids as Innovative Formulations for Drug Delivery
Recent Patents on Drug Delivery & Formulation Development of Heparanase Inhibitors for Anti-Cancer Therapy
Current Medicinal Chemistry Medicinal Plants in Neurodegenerative Diseases: Perspective of Traditional Persian Medicine
Current Drug Metabolism The Therapeutical Potential of a Novel Pterocarpanquinone LQB-118 to Target Inhibitor of Apoptosis Proteins in Acute Myeloid Leukemia Cells
Anti-Cancer Agents in Medicinal Chemistry Retinoid Related Molecules an Emerging Class of Apoptotic Agents with Promising Therapeutic Potential in Oncology: Pharmacological Activity and Mechanisms of Action
Current Pharmaceutical Design Herpes Simplex Viruses in Antiviral Drug Discovery
Current Pharmaceutical Design Signal Transduction and Heavy Ion Radiation Therapy: Biological Mechanisms, Biological Quality Assurance, and New Multimodality Approach
Current Signal Transduction Therapy Sodium Selenite Decreased HDAC Activity, Cell Proliferation and Induced Apoptosis in Three Human Glioblastoma Cells
Anti-Cancer Agents in Medicinal Chemistry Reverse Pharmacognosy: Application of Selnergy, a New Tool for Lead Discovery. The Example of ε-Viniferin
Current Drug Discovery Technologies Chemotherapy and Delivery in the Treatment of Primary Brain Tumors
Current Clinical Pharmacology A Review on Novel Breast Cancer Therapies: Photodynamic Therapy and Plant Derived Agent Induced Cell Death Mechanisms
Anti-Cancer Agents in Medicinal Chemistry Tumor Systems Need to be Rendered Usable for a New Action-Theoretical Abstraction: The Starting Point for Novel Therapeutic Options
Current Cancer Therapy Reviews Targeting the EGFR Pathway for Cancer Therapy
Current Medicinal Chemistry Microarray Technology as a Universal Tool for High-Throughput Analysis of Biological Systems
Combinatorial Chemistry & High Throughput Screening Recent Advances in the Medicinal Chemistry of α-Aminoboronic Acids, Amine-Carboxyboranes and Their Derivatives
Mini-Reviews in Medicinal Chemistry New Promises to Cure Cancer and Other Genetic Diseases/Disorders: Epi-drugs Through Epigenetics
Current Topics in Medicinal Chemistry Therapies of Hematological Malignancies: An Overview of the Potential Targets and Their Inhibitors
Current Chemical Biology Dicoumarol: A Drug which Hits at Least Two Very Different Targets in Vitamin K Metabolism
Current Drug Targets